Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $36
Denali Therapeutics Inc DNLI
$23.02
▼ -5.46%
($-1.33)
⬇️ Below Yest. Low
🗓️ Earnings Next Week
Open
$24.34
Prev Close
$24.35
Day Range
$22.99 – $24.35
52W Range
$12.58 – $27.30
Market Cap
$3.65B
Beta
0.99
EPS (TTM)
$-2.97
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2017-12-08 |
| Shares Out. | 158,710,000 |
| Website | denalitherapeutics.com ↗ |
| Phone | 13026587581 |
| Employees | 507 |
| Net Income | -$128.4M |
| Free Cash Flow | -$419.2M |
| Total Assets | $1.27B |
| Total Liabilities | $339.9M |
| Equity | $926.1M |
About Denali Therapeutics Inc
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Denali Therapeutics Inc is a publicly traded company under the ticker symbol DNLI on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
25 analysts (2026-07-01)